Based on the title and source metadata, this appears to be a patient story related to Crohn's disease and Community and awareness. The original article is from sports.yahoo.com.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Drug Discovery, and Research and clinical trials. The original article is from Molecular Biology Reports.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.

Perianal Crohn’s disease causes major symptoms and affects long-term outcomes; understanding surgical options and the role of combined medical–surgical care can help patients and clinicians plan treatment. The review...

Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...

Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...

People with ulcerative colitis may be interested because the review identifies flavonoids in propolis as compounds that reduce inflammation and strengthen the gut barrier in animal models, and it highlights strategies to...

Researchers are exploring new oral delivery carriers that could deliver drugs directly to inflamed intestinal sites while also modulating immune responses and the gut microbiome. If translated, these approaches might...

A breath-based VOC test could offer a noninvasive, point-of-care way to help detect or screen for colon diseases including IBD. This study shows preliminary promise—especially for ulcerative colitis—but is early-stage...

A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Mansoura Journal of Biology.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from The Egyptian Journal...

Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...

Improving mesalazine delivery could increase drug reaching the colon and potentially improve treatment for ulcerative colitis. A formulation that both enhances dissolution/permeability and offers mechanistic synergy...

The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.

People with HIV can develop colitis that mimics inflammatory bowel disease; treatment and outcomes may differ because infections and HIV-related pathology can cause similar symptoms and can worsen with standard IBD...

People with IBD often ask about dietary supplements. This systematic review suggests some randomized-trial evidence that polyphenol supplements—especially curcumin—may help induce clinical improvement in ulcerative...

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from msn.com.

Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...

A colon-targeted IFX formulation could deliver the drug directly to inflamed tissue, potentially improving effectiveness and lowering systemic side effects or dosing complexity for people with ulcerative colitis.

This study describes how often people newly diagnosed with IBD go on biologic or JAK inhibitor therapy and what happened to them over five years — including hospital visits and surgery — which helps set expectations for...

The study suggests that about one-quarter of IBD patients treated with advanced therapies develop difficult-to-treat disease, and identifies timing of therapy, age, and specific therapy choice as predictors.

People with ulcerative colitis can rarely develop inflammatory complications outside the gut, including central nervous system vasculitis that can look like a brain tumor. Recognizing this can change diagnosis and...

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Pregnancy and fertility. The original article is from hmpgloballearningnetwork.com.

Based on the title and source metadata, this appears to be a video related to Crohn's disease, Inflammatory bowel disease, and Stricture. The original article is from hmpgloballearningnetwork.com.

Based on the title and source metadata, this appears to be a video related to Crohn's disease, Inflammatory bowel disease, and Procedures and surgery. The original article is from hmpgloballearningnetwork.com.

New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.

The study suggests that using Advice & Guidance instead of elective referral was associated with a longer time to diagnosis for IBD, which could influence how primary care referral pathways are evaluated or designed.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from gastroendonews.com.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from gastroendonews.com.

Patients with PsA and clinicians choosing long‑term biologic therapy may care about both durability of PsA control and safety signals for related inflammatory conditions like IBD and uveitis. This analysis reports...

Cure8 found this source from cureus.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Complications. Open the original article for the full details.

New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Infliximab.

The study points to a possible noninvasive brain-based biomarker that correlates with intestinal fibrosis severity in Crohn’s disease, a complication that’s hard to detect and treat. This could eventually help identify...

MRE is a noninvasive imaging test commonly used to evaluate small-bowel Crohn’s disease, especially when disease is beyond the reach of endoscopy or when repeated follow-up imaging is needed. It helps detect...

AMNs are rare but can be malignant and may mimic UC flares or appendicitis, which can delay diagnosis. For people with long-standing UC, awareness may prompt appropriate imaging and surgical referral.

Patients and clinicians exploring new, less-invasive options for fibrostenotic colonic Crohn's disease may be interested because this study reports that intralesional PRP after balloon dilation is feasible and appears...

IBD cases are increasing in Sub-Saharan Africa but care and research remain limited and driven by high-income country priorities. Region-specific research and policy changes could improve diagnosis, treatment access, and...

The study identifies a bacterial mechanism (T6SS) that may help AIEC strains compete with normal gut microbes and colonize the intestinal mucosa — a process relevant to Crohn’s disease biology and future...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring.

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Asian Journal of...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Fatigue, and Remission. The original article is from Crohn's & colitis 360.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Infliximab, and Anti-TNF. The original article is from Frontiers in pediatrics.

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in cell and developmental biology.

The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how...

Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Tests and monitoring. The original article is from Cell Research.

This study raises pharmacovigilance signals and mechanistic hypotheses about liraglutide in people with ulcerative colitis — important because GLP-1 drugs are widely used and are being studied for inflammatory effects....